Future novel therapeutic agents for Clostridium difficile infection

Bibliography

• McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006;12(3):409-15
   PubMed Web of Science ®Google Scholar
• Gerding DN, Muto CA, Owens RC Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008;46(Suppl 1):S43-9
   PubMed Web of Science ®Google Scholar
• Pepin J, Valiquette L, Alary ME, Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171(5):466-72
   PubMed Web of Science ®Google Scholar
• Musher DM, Aslam S, Logan N, Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40(11):1586-90
   PubMed Web of Science ®Google Scholar
• Jobe BA, Grasley A, Deveney KE, Clostridium difficile colitis: an increasing hospital-acquired illness. Am J Surg 1995;169(5):480-3
   PubMed Web of Science ®Google Scholar
• Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007;13(9):1417-9
   PubMed Web of Science ®Google Scholar
• Loo VG, Poirier L, Miller MA, A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353(23):2442-9
   PubMed Web of Science ®Google Scholar
• Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34(3):346-53
   PubMed Web of Science ®Google Scholar
• Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2007;(3):CD004610
   Google Scholar
• Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995;44(RR-12):1-13
   Google Scholar
• Gerding DN, Johnson S, Peterson LR, Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16(8):459-77
   PubMed Web of Science ®Google Scholar
• Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005;5(9):549-57
   PubMed Web of Science ®Google Scholar
• Pelaez T, Alcala L, Alonso R, Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002;46(6):1647-50
   PubMed Web of Science ®Google Scholar
• Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45(3):302-7
   PubMed Web of Science ®Google Scholar
• Young GP, Ward PB, Bayley N, Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 1985;89(5):1038-45
   PubMed Web of Science ®Google Scholar
• Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006;42(6):758-64
   PubMed Web of Science ®Google Scholar
• McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;97(7):1769-75
   PubMed Web of Science ®Google Scholar
• Johnson S, Schriever C, Galang M, Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44(6):846-8
   PubMed Web of Science ®Google Scholar
• Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003;36(5):580-5
   PubMed Web of Science ®Google Scholar
• Lowy I, Molrine DC, Leav BA, Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362(3):197-205
   PubMed Web of Science ®Google Scholar
• Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008;46(Suppl 1):S32-42
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother 2008;52(11):4163-5
   PubMed Web of Science ®Google Scholar
• Finegold SM, Molitoris D, Vaisanen ML, In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004;48(12):4898-902
   PubMed Web of Science ®Google Scholar
• Ackermann G, Loffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004;48(6):2280-2
   PubMed Web of Science ®Google Scholar
• Louie TJ, Emery J, Krulicki W, OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009;53(1):261-3
   PubMed Web of Science ®Google Scholar
• Swanson RN, Hardy DJ, Shipkowitz NL, In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother 1991;35(6):1108-11
   PubMed Web of Science ®Google Scholar
• Babakhani FK, Shangle S, Robert N, Resistance development, cross-resistance, and synergy studies of OPT-80. Abstract E-2047. 44th ICAAC; 30 October – 2 November 2004; Washington, DC, USA
   Google Scholar
• Louie T, Miller M, Donskey C, Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009;53(1):223-8
   PubMed Web of Science ®Google Scholar
• Citron DM, Babakhani F, Goldstein EJ, Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Anaerobe 2009;15(6):234-6
   PubMed Web of Science ®Google Scholar
• Golan Y, Mullane K, Miller M, Low recurrence rate among patients (Pts) with C. difficile infection (CDI) treated with fidaxomicin (FDX). Abstract L1-1639. 49th ICAAC; 12 – 15 September 2009; San Francisco, USA
   Google Scholar
• Gerding D, Sambol S, Nagaro K, Restriction endonuclease analysis (REA) typing of Clostridium difficile in a Phase 3 Treatment Trial of fidaxomicin vs vancomycin: decreased cure rate for epidemic BI/NAP1/027 strain. Abstract L1-1642. 49th ICAAC; 12 – 15 September, 2009. San Francisco, USA
   Google Scholar
• Fox LM, Saravolatz LD. Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 2005;40(8):1173-80
   PubMed Web of Science ®Google Scholar
• Ortiz JJ, Ayoub A, Gargala G, Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Aliment Pharmacol Ther 2001;15(9):1409-15
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001;184(1):103-6
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Hamill RJ, Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;43(4):421-7
   PubMed Web of Science ®Google Scholar
• Broekhuysen J, Stockis A, Lins RL, Nitazoxanide: pharmacokinetics and metabolism in man. Int J Clin Pharmacol Ther 2000;38(8):387-94
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Bressler AM, Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009;48(4):e41-6
   PubMed Web of Science ®Google Scholar
• Bartlett JG. New drugs for Clostridium difficile infection. Clin Infect Dis 2006;43(4):428-31
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Mehendiratta V, Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007;59(4):705-10
   PubMed Web of Science ®Google Scholar
• Xifaxan (rifaximin) tablets [prescribing information]. Palo Alto CSP, 2008
   Google Scholar
• Hartmann G, Honikel KO, Knusel F, Nuesch J. The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochim Biophys Acta 1967;145(3):843-4
   PubMed Web of Science ®Google Scholar
• Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994;14(2):51-6
   PubMedGoogle Scholar
• DuPont HL, Jiang ZD, Okhuysen PC, A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005;142(10):805-12
   PubMed Web of Science ®Google Scholar
• Boero M, Berti E, Morgando A, Verme G. Treatment for colitis caused by Clostridium difficile: results of a randomized, open-label study of rifaximin vs. vancomycin. Microbiologia Medica 1990;5:74-7
   Google Scholar
• Fekety R, Silva J, Kauffman C, Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989;86(1):15-19
   PubMed Web of Science ®Google Scholar
• Garey KW, Jiang ZD, Bellard A, Dupont HL. Rifaximin in treatment of recurrent clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol. 2009;43(1):91-3
   PubMed Web of Science ®Google Scholar
• O'Connor JR, Galang MA, Sambol SP, Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 2008;52(8):2813-17
   PubMed Web of Science ®Google Scholar
• Curry SR, Marsh JW, Shutt KA, High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009;48(4):425-9
   PubMed Web of Science ®Google Scholar
• Noren T, Alriksson I, Akerlund T, In vitro susceptibility to 17 antimicrobials among clinical Clostridium difficile isolates collected 1993 – 2007 in Sweden. Clin Microbiol Infect 2009. [Epub ahead of print]
   PubMedGoogle Scholar
• Jiang ZD, DuPont HL, La Rocco M, Garey KW. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J Clin Pathol 2010;63(4):355-8
   PubMed Web of Science ®Google Scholar
• Van Bambeke F. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Curr Opin Investig Drugs 2006;7(8):740-9
   PubMed Web of Science ®Google Scholar
• Freeman J, Baines SD, Jabes D, Wilcox MH. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 2005;56(4):717-25
   PubMed Web of Science ®Google Scholar
• Somner EA, Reynolds PE. Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob Agents Chemother 1990;34(3):413-19
   PubMed Web of Science ®Google Scholar
• Pelaez T, Alcala L, Alonso R, In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother 2005;49(3):1157-9
   PubMed Web of Science ®Google Scholar
• Wong MT, Kauffman CA, Standiford HC, Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis 2001;33(9):1476-82
   PubMed Web of Science ®Google Scholar
• Montecalvo MA. Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J Antimicrob Chemother 2003;51(Suppl 3):iii31-5
   PubMedGoogle Scholar
• TYGACIL® (tigecycline) [prescribing information]. Philadelphia PWPI, 2009
   Google Scholar
• Hawser SP. Activity of tigecycline against recent European clinical isolates of Clostridium difficile. Int J Antimicrob Agents 2010;35(1):97-8
   PubMed Web of Science ®Google Scholar
• Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986;27(10):1169-72
   PubMed Web of Science ®Google Scholar
• Nord CE, Sillerstrom E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 2006;50(10):3375-80
   PubMed Web of Science ®Google Scholar
• Herpers BL, Vlaminckx B, Burkhardt O, Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009;48(12):1732-5
   PubMed Web of Science ®Google Scholar
• Chen Y-X, Cobana B, Kivel N, Escalating single-dose safety and pharmacokinetics of rifalazil in healthy volunteers. AAPS J 2004;6:M1103
   Google Scholar
• Anton PM, O'Brien M, Kokkotou E, Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters. Antimicrob Agents Chemother 2004;48(10):3975-9
   PubMed Web of Science ®Google Scholar
• Dietze R, Teixeira L, Rocha LM, Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob Agents Chemother 2001;45(7):1972-6
   PubMed Web of Science ®Google Scholar
• Murphy CK, Mullin S, Osburne MS, In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006;50(3):827-34
   PubMed Web of Science ®Google Scholar
• Hoffman FA, Heimbach JT, Sanders ME, Hibberd PL. Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs. Clin Infect Dis 2008;46(Suppl 2):S53-7
   PubMed Web of Science ®Google Scholar
• Elmer GW. Probiotics: “living drugs”. Am J Health Syst Pharm 2001;58(12):1101-9
   PubMed Web of Science ®Google Scholar
• Bruewer M, Luegering A, Kucharzik T, Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 2003;171(11):6164-72
   PubMed Web of Science ®Google Scholar
• Wu X, Vallance BA, Boyer L, Saccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factors. Am J Physiol Gastrointest Liver Physiol 2008;294(1):G295-306
   PubMed Web of Science ®Google Scholar
• Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001;357(9251):189-93
   PubMed Web of Science ®Google Scholar
• Jayamanne VS, Adams MR. Determination of survival, identity and stress resistance of probiotic bifidobacteria in bio-yoghurts. Lett Appl Microbiol 2006;42(3):189-94
   PubMed Web of Science ®Google Scholar
• Masco L, Huys G, De Brandt E, Culture-dependent and culture-independent qualitative analysis of probiotic products claimed to contain bifidobacteria. Int J Food Microbiol 2005;102(2):221-30
   PubMed Web of Science ®Google Scholar
• Drisko J, Bischoff B, Giles C, Evaluation of five probiotic products for label claims by DNA extraction and polymerase chain reaction analysis. Dig Dis Sci 2005;50(6):1113-17
   PubMed Web of Science ®Google Scholar
• Munoz P, Bouza E, Cuenca-Estrella M, Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005;40(11):1625-34
   PubMed Web of Science ®Google Scholar
• Cassone M, Serra P, Mondello F, Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 2003;41(11):5340-3
   PubMed Web of Science ®Google Scholar
• Ledoux D, Labombardi VJ, Karter D. Lactobacillus acidophilus bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin's disease. Int J STD AIDS 2006;17(4):280-2
   PubMed Web of Science ®Google Scholar
• Land MH, Rouster-Stevens K, Woods CR, Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005;115(1):178-81
   PubMed Web of Science ®Google Scholar
• Rautio M, Jousimies-Somer H, Kauma H, Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999 May;28(5):1159-60
   PubMed Web of Science ®Google Scholar
• McFarland LV, Surawicz CM, Greenberg RN, A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271(24):1913-18
   PubMed Web of Science ®Google Scholar
• Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008;(1):CD004611
   Google Scholar
• Surawicz CM, McFarland LV, Greenberg RN, The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31(4):1012-17
   PubMed Web of Science ®Google Scholar
• Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003;35(6-7):365-7
   PubMed Web of Science ®Google Scholar
• Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005;54(Pt 9):905-6
   PubMed Web of Science ®Google Scholar
• Plummer S, Weaver MA, Harris JC, Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004;7(1):59-62
   PubMed Web of Science ®Google Scholar
• Gao XW, Mubasher M, Fang CY, Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated Diarrhea and Clostridium difficile-associated Diarrhea prophylaxis in adult patients. Am J Gastroenterol. [Epub ahead of print]
   Web of Science ®Google Scholar
• Hickson M, D'Souza AL, Muthu N, Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007;335(7610):80
   PubMed Web of Science ®Google Scholar
• Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005;21(5):583-90
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect 1998;36(2):171-4
   PubMed Web of Science ®Google Scholar
• Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342(6):390-7
   PubMed Web of Science ®Google Scholar
• Taylor CP, Tummala S, Molrine D, Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine 2008;26(27-28):3404-9
   PubMed Web of Science ®Google Scholar
• Leav BA, Blair B, Leney M, Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010;28(4):965-9
   PubMed Web of Science ®Google Scholar
• Kyne L. Clostridium difficile – beyond antibiotics. N Engl J Med 2010;362(3):264-5
   PubMed Web of Science ®Google Scholar
• Hecht DW, Galang MA, Sambol SP, In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51(8):2716-19
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Ke S, Palazzini E, In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000;44(8):2205-6
   PubMed Web of Science ®Google Scholar
• Edlund C, Sabouri S, Nord CE. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria. Eur J Clin Microbiol Infect Dis 1998;17(3):193-5
   PubMed Web of Science ®Google Scholar
• Betriu C, Rodriguez-Avial I, Gomez M, Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study. Diagn Microbiol Infect Dis 2006;56(4):437-44
   PubMed Web of Science ®Google Scholar
• McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000;44(9):2254-8
   PubMed Web of Science ®Google Scholar
• Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004;48(11):4430-4
   PubMed Web of Science ®Google Scholar
• Finegold SM, Molitoris D, Vaisanen ML. Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora. Antimicrob Agents Chemother 2009;53(1):281-6
   PubMed Web of Science ®Google Scholar
• Citron DM, Merriam CV, Tyrrell KL, In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother 2003;47(7):2334-8
   PubMed Web of Science ®Google Scholar
• Finegold SM, John SS, Vu AW, In vitro activity of ramoplanin and comparator drugs against anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora. Anaerobe 2004;10(4):205-11
   PubMed Web of Science ®Google Scholar
• Bishara J, Bloch Y, Garty M, Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, Israel. Diagn Microbiol Infect Dis 2006;54(2):141-4
   PubMed Web of Science ®Google Scholar
• Barbut F, Mastrantonio P, Delmee M, Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 2007;13(11):1048-57
   PubMed Web of Science ®Google Scholar
• Sundram F, Guyot A, Carboo I, Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors. J Hosp Infect 2009;72(2):111-8
   PubMed Web of Science ®Google Scholar
• Betriu C, Rodriguez-Avial I, Sanchez BA, Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia. J Antimicrob Chemother 2002;50(5):758-9
   PubMed Web of Science ®Google Scholar
• Golan Y, Mullane K, Miller M, Low recurrence rate among patients (Pts) with C. difficile infection (CDI) treated with fidaxomicin (FDX). Abstract L1-1639. 49th ICAAC; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Gerding D, Sambol S, Nagaro K, Restriction endonuclease analysis (REA) typing of Clostridium difficile in a Phase 3 Treatment Trial of fidaxomicin vs vancomycin: decreased cure rate for epidemic BI/NAP1/027 Strain. Abstract L1-1642. 49th ICAAC; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar